Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
IVInvivyd, Inc. logo

Invivyd, Inc. (IVVD)

NASDAQ Global Market · Currency in USD
$0.61 ▲ +0.00 (+0.54%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.62 ▲ +0.00 (+0.75%)
After hours: Oct 23, 7:13 PM ET

Summary

Previous Close
$0.61
Open
$0.59
Day's Range
$0.58 – $0.62
52 Week Range
$0.53 – $3.07
Volume
2,762,894
Avg. Volume
5,035,201
Market Cap
$180.81M
Beta (5Y Monthly)
0.71
PE Ratio (TTM)
--
EPS (TTM)
-$0.33
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$9.50

Profile: Invivyd, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
122
CEO
Marc William Elia

Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.11 · Revenue est. $15.04M
DateEst.Actual
Aug 13, 2026-$0.11-$0.14Miss
May 14, 2026-$0.08-$0.13Miss
Mar 5, 2026-$0.06$0.02Beat
Nov 6, 2025-$0.05-$0.06Miss
Aug 14, 2025-$0.04-$0.12Miss
May 15, 2025-$0.04-$0.14Miss

Analyst view

Consensus price target
$9.50 ▲ +1,448.7%
Range $9.00 – $10.00
Rating: Buy
Buy 63% · Hold 38% · Sell 0%

Get free alerts on IVVD and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.